Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRJ1 3024

Next Previous
X
Search
Drug Profile

PRJ1 3024

Alternative Names: PRJ1-3024

Latest Information Update: 10 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MingMed Biotechnology
  • Developer MingMed Biotechnology; Xi'An Yufan Biotechnology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Hematopoietic progenitor kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 31 May 2024 Efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 06 Jul 2022 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (PO) (NCT05315167) (MingMed Biotechnology pipeline, July 2022)
  • 06 Jul 2022 Regulatory body approves CTA in Solid tumours in China, prior to July 2022 (MingMed Biotechnology pipeline, July 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top